Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

Improving Quality of Life Using Patient Reported Outcomes Measures Post-operative Via Text Messaging

Not Applicable

Completed

Conditions: Gynecologic Cancer

First Posted Date: 2021-04-21

Last Posted Date: 2023-10-11

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 102

Registration Number: NCT04852471

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Neuroendocrine Tumors
Prostate Cancer Metastatic

Interventions: Drug: Pembrolizumab
Drug: Lenvatinib

First Posted Date: 2021-04-19

Last Posted Date: 2025-02-28

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 50

Registration Number: NCT04848337

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Winship Cancer Instituted of Emory University, Atlanta, Georgia, United States
🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States

and more 2 locations

Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Phase 2

Withdrawn

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Dasatinib
Drug: Ponatinib
Drug: Berlin-Frankfurt-Münster Chemotherapy
Drug: Methotrexate and Cytarabine

First Posted Date: 2021-04-14

Last Posted Date: 2024-02-22

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT04845035

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Sleep Coach: A Mobile App to Address Insomnia Symptoms Among Cancer Survivors

Not Applicable

Completed

Conditions: Insomnia
Prostate Cancer
Colon Cancer
Breast Cancer

First Posted Date: 2021-04-01

Last Posted Date: 2022-11-02

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 30

Registration Number: NCT04827459

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Lighting Intervention for Cancer-related Fatigue

Not Applicable

Completed

Conditions: Breast Cancer
Prostate Cancer
Fatigue
Hematologic Malignancy
Survivorship

First Posted Date: 2021-04-01

Last Posted Date: 2023-10-25

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 139

Registration Number: NCT04827446

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Evaluating a Tailored Cognitive Behavioral Therapy for Adolescent and Young Adult Cancer Patients

Not Applicable

Terminated

Conditions: Depression, Anxiety
Cancer

First Posted Date: 2021-02-26

Last Posted Date: 2022-01-10

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 9

Registration Number: NCT04773197

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

Phase 2

Completed

Conditions: Breast Cancer
Arthralgia

Interventions: Drug: Cannabidiol (CBD)

First Posted Date: 2021-02-15

Last Posted Date: 2025-05-09

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 40

Registration Number: NCT04754399

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Phase 2

Active, not recruiting

Conditions: Prostate Cancer
Castrate Sensitive Prostate Cancer
Oligometastatic Disease

Interventions: Drug: Abiraterone
Drug: Prednisone
Radiation: External Beam Radiotherapy
Biological: Androgen Deprivation Therapy (ADT)
Drug: Olaparib

First Posted Date: 2021-02-10

Last Posted Date: 2025-04-02

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 21

Registration Number: NCT04748042

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Testing the Effect of Mindfulness for Prostatectomy Outcomes

Not Applicable

Terminated

Conditions: Prostate Cancer

First Posted Date: 2021-01-27

Last Posted Date: 2022-10-10

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 1

Registration Number: NCT04727710

Locations: 🇺🇸
University of Rogel Cancer Center, Ann Arbor, Michigan, United States

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer
Metastatic Castration-resistant Prostate Cancer
Metastatic Ovarian Carcinoma
Metastic or Unresectable Pancreatic Adenocarcinoma

Interventions: Drug: Talazoparib
Drug: Belinostat

First Posted Date: 2021-01-11

Last Posted Date: 2025-01-23

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 26

Registration Number: NCT04703920

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy